ReviewInternational journal of molecular sciences2022
Electroconvulsive Therapy in Psychiatric Disorders: A Narrative Review Exploring Neuroendocrine-Immune Therapeutic Mechanisms and Clinical Implications.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- Lack of association between pretreatment glutamate/GABA and major depressive disorder treatment response.Translational psychiatry · 2025Trial
- The Impact of Clinical Characteristics of Patients with Mental Disorders on the Long-Term Effects of Electroconvulsive Therapy.Journal of clinical medicine · 2026Article
- Article
- Electroconvulsive therapy-induced motor seizure length trajectories and their association with clinical remission: a retrospective cohort study across diagnoses.Frontiers in psychiatry · 2026Article
- Physical Therapies and Neuromodulation for Treatment-Resistant Schizophrenia: A Review of Potential Mechanisms, Efficacy, and Safety.Neuropsychiatric disease and treatment · 2026Review
- Article
- Effect of Electroconvulsive Therapy (ECT) on IL-1β, IP-10, IL-17, TNFα, IL-10 and Soluble IL-2 Receptor in Treatment-Resistant Schizophrenia (TRS) Patients-A Preliminary Study.Journal of clinical medicine · 2025Article
- Review
- A Systematic Review of Knowledge, Attitude, and Perception Towards Electroconvulsive Therapy (ECT) in Africa.Neuropsychiatric disease and treatment · 2025Review
- Predictive value of biomarker signatures for suicide risk in hospitalised patients with major depressive disorders: a multicentre study in Shanghai.General psychiatry · 2025Article
- Understanding immune system dysfunction and its context in mood disorders: psychoneuroimmunoendocrinology and clinical interventions.Military Medical Research · 2024Review
- Interventional Psychiatry in India: Bridging Treatment Gaps and Expanding Horizons in Mental Health.Indian journal of psychological medicine · 2024Article
- Neuromodulation Strategies in Lifelong Bipolar Disorder: A Narrative Review.Behavioral sciences (Basel, Switzerland) · 2024Review
- Article
- Electroconvulsive therapy (ECT) and Psychiatric rehospitalization rates: a retrospective study.BMC psychiatry · 2024Article
- Evaluating Anesthesia Practices, Patient Characteristics, and Outcomes in Electroconvulsive Therapy: A Two-Year Retrospective Study.Journal of clinical medicine · 2024Article
- Addressing the stigma and promoting awareness: Electroconvulsive therapy in Pakistan.Health science reports · 2024Article
- Molecular and immunological origins of catatonia.Schizophrenia research · 2024Article
- Electroconvulsive therapy modulates loudness dependence of auditory evoked potentials: a pilot MEG study.Frontiers in psychiatry · 2024Article
- Global research trends and hotspots in Parkinson's disease psychosis: a 25-year bibliometric and visual analysis.Frontiers in aging neuroscience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
Electroconvulsive therapy (ECT) is based on conducting an electrical current through the brain to stimulate it and trigger generalized convulsion activity with therapeutic ends. Due to the efficient use of ECT during the last years, interest in the molecular bases involved in its mechanism of action has increased. Therefore, different hypotheses have emerged. In this context, the goal of this review is to describe the neurobiological, endocrine, and immune mechanisms involved in ECT and to detail its clinical efficacy in different psychiatric pathologies. This is a narrative review in which an extensive literature search was performed on the Scopus, Embase, PubMed, ISI Web of Science, and Google Scholar databases from inception to February 2022. The terms "electroconvulsive therapy", "neurobiological effects of electroconvulsive therapy", "molecular mechanisms in electroconvulsive therapy", and "psychiatric disorders" were among the keywords used in the search. The mechanisms of action of ECT include neurobiological function modifications and endocrine and immune changes that take place after ECT. Among these, the decrease in neural network hyperconnectivity, neuroinflammation reduction, neurogenesis promotion, modulation of different monoaminergic systems, and hypothalamus-hypophysis-adrenal and hypothalamus-hypophysis-thyroid axes normalization have been described. The majority of these elements are physiopathological components and therapeutic targets in different mental illnesses. Likewise, the use of ECT has recently expanded, with evidence of its use for other pathologies, such as Parkinson's disease psychosis, malignant neuroleptic syndrome, post-traumatic stress disorder, and obsessive-compulsive disorder. In conclusion, there is sufficient evidence to support the efficacy of ECT in the treatment of different psychiatric disorders, potentially through immune, endocrine, and neurobiological systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.